
GLP-1 Diabetes Drugs Linked to Notable Drop in Addiction Rates
A UT El Paso study of more than 142,000 adults with type 2 diabetes or obesity found that GLP-1 medications (including Ozempic) were associated with substantially lower rates of several substance-use disorders—74% lower for alcohol, 69% for opioid, 68% for nicotine, and 75% for cocaine—compared with similar patients not on GLP-1s. Researchers caution that this is observational and not proof of prevention; randomized trials are needed, and the team plans prospective studies to see if GLP-1 therapy changes substance use and mental health outcomes.












